Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects
Condition(s):FXILast Updated:May 17, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):FXILast Updated:May 17, 2023Recruiting
Condition(s):Advanced Malignant Solid NeoplasmLast Updated:September 21, 2023Recruiting
Condition(s):Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Recurrent Grade 3b Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Grade 3b Follicular LymphomaLast Updated:November 21, 2023Withdrawn
Condition(s):KRAS NP_004976.2:p.G12D; Metastatic Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8Last Updated:September 29, 2023Active, not recruiting
Condition(s):HypercholesterolemiaLast Updated:July 7, 2022Recruiting
Condition(s):Pachyonychia CongenitaLast Updated:November 19, 2008Completed
Condition(s):Metastatic Melanoma; Absence of CNS MetastasesLast Updated:January 23, 2014Completed
Condition(s):Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH); Genetic Risk FactorLast Updated:January 25, 2024Not yet recruiting
Condition(s):Chronic Myeloid LeukemiaLast Updated:February 18, 2009Completed
Condition(s):Paroxysmal Nocturnal Hemoglobinuria (PNH)Last Updated:November 18, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.